Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expected in…
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r)…
SEOUL, South Korea, May 13, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a…
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015…
sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December…
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has…
Revenues Increased 12% to $28.3 Million, Including the Renewal of Two Delayed Contracts with the New York City Police Department…
Delivered Revenue and Adjusted EBITDA in the top end of Guidance Range First Quarter Revenue Growth Roughly Flat Year-Over-Year; Revenue…
Achieves Revenue In Line With Expectations With Record Gross MarginVIENNA, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Urgent.ly Inc. (Nasdaq:…
DENVER, May 13, 2025 (GLOBE NEWSWIRE) -- authID® (Nasdaq: AUID) (“authID” or the “Company”), a leading provider of biometric identity verification…
This website uses cookies.